Results 131 to 140 of about 17,757 (259)

Unraveling the Physicochemical Landscape of Organoselenium Compounds in Nanocarrier Systems

The Chemical Record, EarlyView.
Main nanocarriers employed to enhance the bioavailability and transport of organoselenium compounds. The image illustrates the key interaction forces that stabilize these organoselenium species in solution, enabling their application in drug delivery systems, catalysis, photoelectronic devices, and sensing technologies. In recent years, publications on
Romelly Eugenia Rojas Ramírez, Tielle Moraes de Almeida, Daiani Canabarro Leite, Gilson Zeni   +3 more
wiley   +1 more source

Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor

Gynecologic Oncology Reports, 2016
Melissa Schwartz, Gloria S. Huang
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Reproductive and sexual sequelae of neuroendocrine tumour therapies: an under-recognised challenge. [PDF]

Endocr Relat Cancer
Shekhda KM, Shah PM, Biddanda A, Grossman A, Caplin M.   +4 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. [PDF]

J Urol
Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EPM, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ.   +17 more
europepmc   +1 more source

Penile Electromyography in the Diagnosis of Impotence [PDF]

, 1994
Bruyne, R. de, Keuppens, F., Merckx, L., Schmedding, E., Stief, Christian Georg   +4 more
core   +1 more source

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Recurrent ventricular asystole during octreotide infusion in a patient with pancreatic neuroendocrine tumor: a case report. [PDF]

J Med Case Rep
Mansolas N, Nesbitt I.
europepmc   +1 more source

Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells [PDF]

, 1990
Berkovic, D., Doenecke, D., Eibl, H., Hochhuth, C., Unger, C.   +4 more
core